A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping (SAFARI44)

August 21, 2026 updated by: Avidity Biosciences, Inc.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study consists of a Screening Period of up to 44 Days, a Randomized 54 Week Treatment Period, a 54 Week Open Label Extension (OLE), and a Follow-Up Period of 6 weeks. Participants will be randomized to receive an intravenous infusion of either delpacibart-zotadirsen or placebo at the clinical study site every 6 weeks for a total of 9 doses. After completion of the randomized treatment period, all participants may enter the OLE portion of the study consisting of 9 doses of AOC 1044 regardless of group assignment in the randomized period. The final dose will occur at Week 102, followed by a final assessment at Week 108 and a safety follow-up visit at Week 114. An Independent Data Monitoring Committee (IDMC) comprising members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals.

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Belgium
      • Leuven, Belgium
        • Recruiting
        • UZ Leuven
      • Liège, Belgium
        • Recruiting
        • Centre Hospitalier Regional de la Citadelle
  • France
      • Paris, France
        • Recruiting
        • AP-HP Hospital Armand-Trousseau
  • Germany
      • Essen, Germany
        • Recruiting
        • Universitaetsklinikum Essen
      • Heidelberg, Germany
        • Recruiting
        • Universitaetsklinikum Heidelberg
      • München, Germany
        • Recruiting
        • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
  • Italy
      • Milan, Italy
        • Recruiting
        • Fondazione Serena ETS - Centro Clinico NeMO Milano
      • Roma, Italy
        • Recruiting
        • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universitario Cattolica del Sacro Cuore
  • Spain
      • Barcelona, Spain
        • Recruiting
        • Hospital Sant Joan de Deu
      • Madrid, Spain
        • Recruiting
        • Hospital Universitario La Paz
      • Seville, Spain
        • Recruiting
        • Hospital Viamed Santa Angela De la Cruz - FutureMeds Spain
  • United Kingdom
      • Newcastle, United Kingdom
        • Recruiting
        • Royal Victoria Infirmary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Ambulatory males with clinical and genetic diagnosis of DMD
  • Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping
  • 7 to 16 years of age at time of consent
  • TTR and NSAA assessment completed within the protocol specified parameters at Screening
  • On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.

Key Exclusion Criteria:

  • Previous treatment cell or gene therapy.
  • Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).
  • Lab values outside of the protocol specified range at Screening
  • If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:
  • Less than 1 month, for growth hormone and/or testosterone
  • Less than 6 months for givinostat

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AOC 1044
Participants will receive AOC 1044 intravenously (IV) every 6 weeks (Q6W) during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which the same participants will continue to receive AOC 1044 IV Q6W
Drug: AOC 1044
AOC 1044 will be administered by intravenous (IV) infusion
Placebo Comparator: Placebo
Participants will receive placebo (saline) IV Q6W during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which all participants will then receive AOC 1044 IV Q6W
Drug: Placebo
Placebo will be administered by intravenous (IV) infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from Baseline in Time to Rise (TTR) Velocity at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Creatine Kinase (CK) at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in 4-Stair Climb (4SC) Velocity at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in 10-Meter Walk/Run Test (10MWRT) Velocity at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in Stride Velocity 95th Centile (SV95C) at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in DMD Quality of Life (DMD-QoL) Score at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in Patient Global Impression of Severity (PGI-S) at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Change from Baseline in Caregiver Global Impression of Severity (CaGI-S) at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54
Patient Global Impression of Change (PGI-C) at Week 54
Time Frame: Week 54
Week 54
Caregiver Global Impression of Change (CaGI-C) at Week 54
Time Frame: Week 54
Caregiver Global Impression of Change (CaGI-C) at Week 54
Week 54
Change from Baseline in Quantitative Muscle Testing (QMT) at Week 54
Time Frame: Baseline, Week 54
Baseline, Week 54

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Avidity Biosciences, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

May 1, 2029

Study Completion (Estimated)

July 1, 2030

Study Registration Dates

First Submitted

May 8, 2026

First Submitted That Met QC Criteria

May 8, 2026

First Posted (Actual)

May 14, 2026

Study Record Updates

Last Update Posted (Actual)

August 24, 2026

Last Update Submitted That Met QC Criteria

August 21, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AOC 1044-CS3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe